Experimental drug PTX-100 tested in advanced cancer patients
Disease control
Completed
This early-phase study tested a new drug called PTX-100 in 25 people with advanced cancers (like multiple myeloma, lymphoma, or pancreatic cancer) that had stopped responding to standard treatments. The goal was to find the safest dose and see how the drug works in the body. Whil…
Phase: PHASE1 • Sponsor: Prescient Therapeutics, Ltd. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC